Moderna, Inc. (MRNA)

Moderna's commercial portfolio is anchored almost entirely by its COVID-19 vaccine franchise, which now operates at a fraction of the revenue scale that defined the company between 2021 and 2022, and the pace at which new products can replace that volume is the central question determining this company's fundamental trajectory. Total revenue in FY2025 was $1.9 billion, down 39% from $3.2 billion in FY2024 and down from $6.8 billion in FY2023, a three-year collapse that reflects the normalization of COVID vaccination demand globally. The next-generation COVID vaccine mNEXSPIKE, launched in the U.S. in mid-2025, has shown early commercial traction, representing approximately 24% of U.S. retail COVID vaccinations in 2025 and approaching one-third of vaccinations among adults aged 65 and older. Q2 2026 revenue of $145 million was up 2% from $142 million in the year-prior period, demonstrating stability rather than recovery at current volumes.

The RSV vaccine mRESVIA received approval in Mexico and a label expansion in Australia, and Moderna signed a joint procurement contract with the European Commission for up to 24 million doses across six countries. Long-term strategic partnerships in the United Kingdom, Canada, and Australia provide some revenue visibility: the Q1 2026 quarter was supported primarily by execution of the UK partnership agreement, contributing to $389 million in Q1 2026 revenue, a meaningful but non-recurring quarterly uplift. Management guided FY2026 revenue growth of up to 10% over FY2025, which at the midpoint implies approximately $2.1 billion in full-year revenue, still modest relative to the company's cost base. Cost of sales guidance was lowered from $1.8 billion to $1.7 billion in the Q2 2026 call, reflecting manufacturing efficiency gains, but operating expenses of approximately $4.2 billion in FY2025 leave the operating loss structure largely intact regardless of near-term production savings.

The most material near-term catalyst for re-rating is the oncology pipeline, specifically the personalized cancer vaccine program intismeran autogene, developed in collaboration with Merck & Co., Inc. Moderna and Merck announced on August 19, 2026, that the Phase 3 melanoma trial had met its primary endpoints, reporting a 49% reduction in the risk of recurrence or death over five years when combined with Merck's KEYTRUDA in the adjuvant setting. Underlying data are scheduled for presentation on October 24, 2026. The U.S. National Institutes of Health is also launching a major public-private initiative to fast-track therapeutic cancer vaccines targeting pancreatic, liver, and colorectal cancers. Additionally, Moderna anticipates potential first approvals of influenza and flu-COVID combination products in 2026. These pipeline developments are the source of the market's willingness to assign a premium multiple to a company with deeply negative current financials, and execution risk around regulatory timelines and commercial uptake of next-generation products remains the primary constraint on the investment case.

Moderna closed a strategic collaboration agreement with Recordati S.p.A. on March 16, 2026, covering the rare metabolic disease candidate mRNA-3927 for propionic acidemia. Under the terms, Moderna received an upfront payment of $50 million and is eligible for up to $110 million in development and regulatory milestone payments, with additional commercial milestones and tiered royalties thereafter. Moderna will lead clinical development through approval, while Recordati will lead commercialization, leveraging its established rare disease commercial infrastructure. The transaction is financially modest relative to Moderna's operating cost base but confirms a strategic pivot toward sharing clinical development risk and securing non-dilutive milestone capital to partially offset operating cash outflows. The $50 million upfront is not material to the valuation thesis, but the milestone structure, if achieved, could provide incremental non-dilutive funding across a multi-year horizon. The deal is neither price appreciative nor deteriorative in isolation; its significance is structural, validating Moderna's rare disease program and reducing the capital burden on a company burning approximately $2 billion in FCF annually.

Two senior Moderna executives conducted material open-market share sales in the six months ending October 22, 2026, collectively disposing of over $22 million in stock at prices between $134 and $221, which broadly contradicts the cautionary signal on current fundamentals by suggesting insiders are monetizing at current elevated price levels. Chief Financial Officer James Mock exercised options and sold a combined 34,836 shares on September 10, 2026, at $134.49 per share for total sale proceeds of approximately $4.7 million. President Stephen Hoge exercised options and sold a combined 78,369 shares across October 14 and 15, 2026, at prices between $213.47 and $220.72 per share, generating total proceeds of approximately $17.9 million. Both transactions involved option exercises at strike prices well below market, with the net proceeds reflecting the spread between the exercise price and the prevailing market price rather than purely discretionary purchases at market. The fact that both executives elected to sell the full or near-full option position rather than hold the newly acquired shares is a signal worth monitoring in the context of the price level relative to pipeline-driven expectations.

Analyst opinion on Moderna is sharply divided as of October 2026, with sell-side price targets ranging from $80 to $180, reflecting genuine disagreement about whether the pipeline recovery can justify current valuation levels. The current consensus is seven buy ratings, fourteen holds, and four sells as of late October 2026. On the cautionary side, Citigroup downgraded to Sell on September 30, 2026, with a $80 price target, and Rothschild & Co downgraded to Sell on September 3, 2026, with an $81 target. On the constructive side, Argus Research upgraded to Buy on August 28, 2026, with a $180 target, Piper Sandler raised its target from $77 to $167 on August 20, 2026, maintaining Overweight, and TD Cowen raised its target from $40 to $90 on October 21, 2026, while maintaining a Hold rating. William Blair, CLSA, and Bradesco Corretora each upgraded to Outperform or equivalent on August 19,28, 2026, and Wolfe Research moved from Underperform to Peer Perform on August 25, 2026. The TTM diluted Earnings Per Share (EPS) of -$7.98 implies no embedded positive earnings in the current price, and the P/B of 12.1x reflects the market pricing in a multi-year pipeline success scenario rather than current earnings power. Forward analyst estimate revisions are trending downward. Forward estimate revisions following the Q2 2026 quarter are being monitored.

Moderna conducted no share repurchases in FY2025, a continuation of the suspension of its buyback program from FY2024, as the company prioritizes cash preservation during a period of sustained operating cash outflows. In FY2023, the company repurchased approximately $1.2 billion in common stock, but that program has not been reinstated since. The diluted share count has remained broadly flat, moving from 382 million weighted average shares in FY2023 to 384 million in FY2024 and 389 million in FY2025, with minimal dilution from employee stock option exercises partially offset by stock-based compensation issuances. With no dividends paid and no buyback activity, the total capital return yield to shareholders is 0%, against a negative FCF, making any comparison of capital return to FCF moot in the current period. Capital expenditure in FY2025 was $192 million, or approximately 10% of FY2025 revenue, down from $1.05 billion in FY2024 when roughly 33% of revenue was directed to manufacturing infrastructure buildout. The sharp reduction in capex reflects the completion of major manufacturing capacity investments, including licensed facilities in the United Kingdom, Canada, and Australia. Management lowered cost of sales guidance from $1.8 billion to $1.7 billion for FY2026 at the Q2 2026 earnings call, signaling continued focus on cost reduction rather than expansion spending. Moderna does not carry a public credit rating from Moody's or S&P.